India's pharma and healthcare sectors maintain investment appeal despite volume decline
The Indian pharma and healthcare sector has witnessed a 298% jump in deals during the third quarter of 2023 compared to the same period last year.
Despite a 32% decline in deal volumes, with 26 deals amounting to $2.7 billion, the surge in deal values was notable. This surge was primarily driven by two high-value transactions exceeding $650 million each and four deals valued at over $100 million each.
Investments in India have continued to focus on the active pharmaceutical ingredient (API) and Contract Development and Manufacturing Organization (CDMO) segments within the life sciences and single specialty areas in healthcare. The API segment in life sciences, in particular, has consistently garnered interest.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze